Press Room

	Press Releases
	Definiens in the News
	Definiens Press Kit English
	Definiens Press Kit German
	Management Photo Download
	Press Archive

Events

IN-SIGHT Online Events

IN-SIGHT Newsletter

back

Definiens and Cenix BioScience Enter into Licensing and Co-Marketing Agreement in High-Content Screening

Munich/Dresden - May 09, 2005 - Definiens, a leading provider of advanced image analysis solutions, and Cenix BioScience, the leading specialist in advanced RNA interference (RNAi)-based research services, announced today that they have entered into a licensing and co-marketing agreement. This step represents the formalization of an ongoing and strong relationship, as the two companies have been working together for several years now.

The two companies' offerings are ideally complementary and the agreement will therefore build on their inherent synergies. Cenix is providing research services for the life science industry and academic groups, focusing on the combination of high throughput (HT) RNAi with high content (HC) assays in human and rodent cells. For those groups capable of carrying out such large scale studies themselves, Definiens is providing its uniquely powerful image analysis software system, Cellenger®, based on Definiens' Cognition Network Technology.

As Cenix has constantly sought to further strengthen its capabilities in microscopy-based screening and automated image analysis, its scientists have tested a wide range of third party solutions from academia and industry efforts alike. Its early analysis of Cellenger® software in the context of genome-scale RNAi-based screens in human cells convinced Cenix to invest further efforts in assisting Definiens with the development and marketing of this world-class package.

"The combination of these technologies will be crucial to solidify Cenix' leadership in providing the best and most efficient high content read-out capabilities to our customers" said Christophe Echeverri, CEO/CSO of Cenix BioScience.

Definiens, having recognized Cenix's leading global position in the field of HT/HC-RNAi based experimentation, has welcomed such specialized input on precisely those cell-based applications that have now emerged a key driver for a wide range of life science research fields.

"Through this alliance, we begin realizing the strong synergies that exist between Definiens and Cenix in the field of high-content screening", said Thomas Heydler, Chief Executive Officer of Definiens. "With our leading-edge Cellenger® HCS solution we offer a comprehensive application for automated image analysis and our collaboration with Cenix will allow us to reach a new form of excellence in the HCS market."

Cenix BioScience is using Cellenger® for the development and implementation of multi-parameter assays for HT-RNAi studies in cultured human and rodent cells for target discovery and validation, as well as analyses of drug modes of action. Under the terms of the agreement Cenix gets broad access to Cellenger® software, which will be integrated into its existing HT/HC-RNAi-based research infrastructure, enabling the widest possible range of advanced microscopy-based assays in the context of its research service offerings.

The Definiens Cellenger® HCS solution is an advanced software system for the powerful automated high-content analysis of cell-based assays that enable reliable and fully automated data extraction. The Cellenger® HCS solution allows detailed analysis of structures of interest even in complex image data and the extracted objects are counted and morphometrically measured. Definiens will receive product development and marketing assistance from Cenix through beta-testing feedback, data sharing and reference site support.

Commercial terms of the worldwide, non-exclusive agreement were not disclosed.